Acadia Pharmaceuticals Inc (NASDAQ:ACAD)’s traded shares stood at 1.55 million during the last session, with the company’s beta value hitting 0.65. At the close of trading, the stock’s price was $21.74, to imply a decrease of -2.51% or -$0.56 in intraday trading. The ACAD share’s 52-week high remains $25.23, putting it -16.05% down since that peak but still an impressive 38.36% since price per share fell to its 52-week low of $13.40. The company has a valuation of $3.64B, with an average of 1.53 million shares in intraday trading volume over the past 10 days and average of 2.07 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Acadia Pharmaceuticals Inc (ACAD), translating to a mean rating of 1.89. Of 16 analyst(s) looking at the stock, 1 analyst(s) give ACAD a Sell rating. 0 of those analysts rate the stock as Overweight while 1 advise Hold as 14 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at 0.14.
Acadia Pharmaceuticals Inc (NASDAQ:ACAD) trade information
After registering a -2.51% downside in the last session, Acadia Pharmaceuticals Inc (ACAD) has traded red over the past five days. The 5-day price performance for the stock is 1.87%, and 26.40% over 30 days. With these gigs, the year-to-date price performance is 18.47%. Short interest in Acadia Pharmaceuticals Inc (NASDAQ:ACAD) saw shorts transact 16.66 million shares and set a 5.73 days time to cover.
The extremes give us $20 and $32 for target low and target high price respectively. As such, ACAD has been trading -47.19% off suggested target high and 8.0% from its likely low.
Acadia Pharmaceuticals Inc (ACAD) estimates and forecasts
The rating firms project that company’s revenue will grow 11.18% compared to the previous financial year.
Revenue forecast for the current quarter as set by 17 analysts is 263.06M. Meanwhile, for the current quarter, a total of 17 analyst(s) estimate revenue growth to 274.53M.Earnings reports from the last fiscal year show that sales brought in 241.96M and 250.4M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 8.72% before jumping 9.63% in the following quarter.
ACAD Dividends
Acadia Pharmaceuticals Inc has its next earnings report out on 2025-May-06. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Acadia Pharmaceuticals Inc (NASDAQ:ACAD)’s Major holders
Acadia Pharmaceuticals Inc insiders hold 0.68% of total outstanding shares, with institutional holders owning 105.61% of the shares at 106.33% float percentage. In total, 105.61% institutions holds shares in the company, led by BAKER BROS. ADVISORS LP. As of 2024-06-30, the company held over 42.88 million shares (or 25.9001% of shares), all amounting to roughly $696.77 million.
The next major institution holding the largest number of shares is VANGUARD GROUP INC with 13.71 million shares, or about 8.2827% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $222.82 million.
We also have iShares Trust-iShares Core S&P Small-Cap ETF and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund as the top two Mutual Funds with the largest holdings of the Acadia Pharmaceuticals Inc (ACAD) shares. Going by data provided on Apr 30, 2025 , iShares Trust-iShares Core S&P Small-Cap ETF holds roughly 7.48 shares. This is just over 4.47% of the total shares, with a market valuation of $162.65 million. Data from the same date shows that the other fund manager holds a little less at 3.94, or 2.35% of the shares, all valued at about 85.68 million.
